---
title: "AI-driven Test-free Claims Model Predicts Trajectory Events in Fibrotic Interstitial Lung Disease"
id: "medrxiv-5-natural-history-of-fibrotic-interstitial-lung-disease-using-ai-driven-test-free"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-5-natural-history-of-fibrotic-interstitial-lung-disease-using-ai-driven-test-free"
content_type: "clinical_feed_article"
specialty: "Pulmonology"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1?rss=1"
published_at: "2026-08-22T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# AI-driven Test-free Claims Model Predicts Trajectory Events in Fibrotic Interstitial Lung Disease
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-5-natural-history-of-fibrotic-interstitial-lung-disease-using-ai-driven-test-free
- **Specialty:** [Pulmonology](https://medichelpline.com/clinical-feed/pulmonology.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1?rss=1)
- **Published At:** 2026-08-22T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- This study developed a test-free, claims-based digital-twin framework (ZeBRA) to generate individualized, time-updated forecasts for patients with **fibrosing ILD**, including **IPF**, using de-identified longitudinal administrative claims. - The analytic cohort comprised 345,918 patients with fibrosing ILD, of whom 17,284 had IPF; models used evolving diagnosis, pharmacy, and procedure codes from Merative MarketScan Commercial and Medicare Supplemental databases. - Horizon-specific models forecast seven claims-observable events: supplemental oxygen escalation, pulmonary hypertension, an acute respiratory failure/ARDS composite, nausea, diarrhea, liver injury, and gastrointestinal bleeding. - Predictions were evaluated in a time-updated follow-up setting at 1-month, 6-month, and 1-year horizons to provide near-term and longer-term risk estimates. - Predictive discrimination was consistent across events and horizons: in fibrosing ILD AUCs ranged from 0.691 (liver injury at 1 year) to 0.912 (oxygen dependence at 1 month); PPVs ranged from 0.189 to 0.714 across outcomes and horizons. - At 1 month in the full fibrosing ILD cohort, oxygen dependence achieved AUC 0.912 ± 0.005 with PPV 0.473 ± 0.005; pulmonary hypertension achieved AUC 0.881 ± 0.005 with PPV 0.539 ± 0.005. - In the IPF subcohort, AUCs ranged from 0.687 to 0.855 and PPVs from 0.245 to 0.817; at 1 month PPV was 0.753 ± 0.015 for oxygen dependence and 0.817 ± 0.011 for pulmonary hypertension. - The approach requires no imaging, pulmonary function tests, laboratory data, clinical notes, or patient-facing data collection and could support low-burden reassessment, anticipatory care planning, and earlier recognition of elevated near-term risk. - Code and an API implementation for the pulmonary hypertension prediction pipeline are available at the authors' GitHub; source claims data cannot be publicly released and are subject to data-use agreements. - The authors declared no competing interests and report that institutional review board approval covered use of de-identified MarketScan data under the noted protocol.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=R6EssMvAKSrKz_JQ0MMWJsNs9JzZT6JpA3k2YZAm2QM-1787457567.6030345-1.2.1.1-DB0vptmQTGanlzRuP6FxZaJjppwbnzn.eqspaeKfz1wWrsz_Nx9NEzlf5sFKsdIL) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Natural History of Fibrotic Interstitial Lung Disease using AI-driven Test-free Assessment of Routine EHR Dmytro Onishchenko, Fernando Martinez, Anthony N. Gerber, Edward Cantu, Girish Nair, Ishanu Chattopadhyay doi: https://doi.org/10.64898/2026.08.19.26360827 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Dmytro Onishchenko 1 University of Kentucky; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dmytro%2BOnishchenko%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Onishchenko%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADmytro%2BOnishchenko%2B) Fernando Martinez 2 University of Massachusetts * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Fernando%2BMartinez%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Martinez%20F&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AFernando%2BMartinez%2B) Anthony N. Gerber 1 University of Kentucky; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Anthony%2BN.%2BGerber%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Gerber%20AN&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AAnthony%2BN.%2BGerber%2B) Edward Cantu 1 University of Kentucky; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Edward%2BCantu%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Cantu%20E&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AEdward%2BCantu%2B) Girish Nair 1 University of Kentucky; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Girish%2BNair%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Nair%20G&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AGirish%2BNair%2B) Ishanu Chattopadhyay 1 University of Kentucky; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ishanu%2BChattopadhyay%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Chattopadhyay%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIshanu%2BChattopadhyay%2B) * For correspondence: ishanu_ch@uky.edu * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1283956/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1283956/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1283956/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1283956/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1283956/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Rationale: Fibrosing interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), have heterogeneous postdiagnosis courses. Existing prognostic tools often rely on pulmonary function testing, imaging, or laboratory data that may not be uniformly available and rarely provide individualized, time-updated forecasts of multiple clinically relevant trajectory events. Objectives: To determine whether longitudinal healthcare claims can generate test-free, time-updated forecasts of clinically actionable postdiagnosis trajectory events in patients with fibrosing ILD and IPF. Methods: Using de-identified longitudinal administrative claims from the Merative MarketScan Commercial Claims and Encounters and Medicare Supplemental and Coordination of Benefits databases, we constructed code-based digital twins (ZeBRA) encoding each patient's evolving diagnosis, pharmacy, and procedure history. Horizon-specific models forecast seven claims-observable events: supplemental oxygen escalation, pulmonary hypertension, acute respiratory failure/ARDS composite, nausea, diarrhea, liver injury, and gastrointestinal bleeding. The analytic cohort included 345,918 patients with fibrosing ILD, including 17,284 with IPF. Predictions were evaluated in a time-updated follow-up setting at 1-month, 6-month, and 1-year horizons. Results: Predictive discrimination was consistent across events and horizons. In fibrosing ILD, AUC ranged from 0.691 for liver injury at 1 year to 0.912 for oxygen dependence at 1 month, with PPV ranging from 0.189 to 0.714. At 1 month, oxygen dependence achieved an AUC of 0.912 +/- 0.005 with PPV of 0.473 +/- 0.005, and pulmonary hypertension achieved an AUC of 0.881 +/- 0.005 with PPV of 0.539 +/- 0.005. The IPF subcohort showed analogous horizon-dependent performance, with AUC ranging from 0.687 to 0.855 and PPV from 0.245 to 0.817. At 1 month in IPF, PPV was 0.753 +/- 0.015 for oxygen dependence and 0.817 +/- 0.011 for pulmonary hypertension. Conclusions: A test-free digital-twin framework derived from routine longitudinal claims can provide individualized, time-updated forecasts of actionable fibrosing ILD and IPF trajectory events without imaging, pulmonary function tests, laboratory data, clinical notes, or patient-facing data collection. These forecasts may support low-burden reassessment, anticipatory care planning, and earlier recognition of elevated near-term risk for respiratory deterioration or management-altering complications. ### Competing Interest Statement The authors have declared no competing interest. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study used de-identified longitudinal administrative claims data from the Merative MarketScan Research Databases and conforms to Merative DUA stipulations. The University of Kentucky (UK) IRB approved use of the de-identified Merative MarketScan database for UK researchers using only Merative MarketScan data not linked with another database (IRB protocol 43542). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability A functioning API implementation of the full ZeBRA pulmonary hypertension prediction pipeline, including model input processing and risk-score generation is available at https://github.com/zeroknowledgediscovery/ZeBRA_nhfild. Source data used for model training and validation consist of de-identified longitudinal administrative claims and are subject to data-use agreements with their respective data owners; these data cannot be publicly released. Derived summary statistics and scripts sufficient to reproduce the main analyses are available upon reasonable request. Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.19.26360791v1 "Effects of low-dose iron supplementation on iron status, safety outcomes and gut microbiota in female soccer players: a randomized controlled study")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.19.26360845v1 "Effects of oral hygiene and food intake on tongue swab testing for tuberculosis in South Africa") Posted August 22, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/08/22/2026.08.19.26360827.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.19.26360827v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/08/22/2026.08.19.26360827.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Natural History of Fibrotic Interstitial Lung Disease using AI-driven Test-free Assessment of Routine EHR Dmytro Onishchenko, Fernando Martinez, Anthony N. Gerber, Edward Cantu, Girish Nair, Ishanu Chattopadhyay medRxiv 2026.08.19.26360827; doi: https://doi.org/10.64898/2026.08.19.26360827 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360827v1%26text%3DNatural%2520History%2520of%2520Fibrotic%2520Interstitial%2520Lung%2520Disease%2520using%2520AI-driven%2520Test-free%2520Assessment%2520of%2520Routine%2520EHR "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360827v1%26t%3DNatural%2520History%2520of%2520Fibrotic%2520Interstitial%2520Lung%2520Disease%2520using%2520AI-driven%2520Test-free%2520Assessment%2520of%2520Routine%2520EHR "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360827v1%26title%3DNatural%2520History%2520of%2520Fibrotic%2520Interstitial%2520Lung%2520Disease%2520using%2520AI-driven%2520Test-free%2520Assessment%2520of%2520Routine%2520EHR%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.19.26360827v1%26title%3DNatural%2520History%2520of%2520Fibrotic%2520Interstitial%2520Lung%2520Disease%2520using%2520AI-driven%2520Test-free%2520Assessment%2520of%2520Routine%2520EHR "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.19.26360827) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.19.26360827v1&count=horizontal&via=&text=Natural%20History%20of%20Fibrotic%20Interstitial%20Lung%20Disease%20using%20AI-driven%20Test-free%20Assessment%20of%20Routine%20EHR&counturl=www.medrxiv.org/content/10.64898/2026.08.19.26360827v1 "Tweet This") ## Subject Area * [Respiratory Medicine ](https://www.medrxiv.org/collection/respiratory-medicine) Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (609) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (891) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (324) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4736) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (473) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (404) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (637) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1608) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15768) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1193) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6945) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (723) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1049) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4938) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1419) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1729) * [Hematology](https://www.medrxiv.org/collection/hematology) (574) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1323) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16219) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1155) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (657) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (150) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (715) * [Neurology](https://www.medrxiv.org/collection/neurology) (7134) * [Nursing](https://www.medrxiv.org/collection/nursing) (359) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1068) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1218) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (992) * [Oncology](https://www.medrxiv.org/collection/oncology) (3557) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1030) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (387) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (442) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (463) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (138) * [Pathology](https://www.medrxiv.org/collection/pathology) (702) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1764) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (730) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (756) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5799) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9644) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2364) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1421) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1234) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (631) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (761) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (571) * [Surgery](https://www.medrxiv.org/collection/surgery) (756) * [Toxicology](https://www.medrxiv.org/collection/toxicology) (106) * [Transplantation](https://www.medrxiv.org/collection/transplantation) (300) * [Urology](https://www.medrxiv.org/collection/urology) (285) Evaluation/discussion of this paper x Comments 0TRiP 0Community
## Related Clinical Research

- [Determinants of Favorable MDR-TB Treatment Outcomes in Zambia, 2018–2022](https://medichelpline.com/clinical-feed/plos-one-16-determinants-of-favorable-treatment-outcomes-in-multidrug-resistant.md)
- [Spatial patterns and economic burden of comorbidities in hospitalised pulmonary tuberculosis patie](https://medichelpline.com/clinical-feed/pubmed-42663079.md) (DOI: 10.7189/jogh.16.04284)
- [Sotatercept in Chinese PAH Patients: Early Single-Center Case Series Outcomes](https://medichelpline.com/clinical-feed/pubmed-42557069.md) (DOI: 10.3760/cma.j.cn112147-20260401-00176)
- [Bupropion Hydrochloride for Improving Recovery in Acute Ischaemic Stroke: BASE Trial Protocol](https://medichelpline.com/clinical-feed/bmj-open-4-protocol-for-base-a-multicentre-double-blind-randomised-controlled-trial-of.md)
- [Risk of Systemic Rheumatic Diseases in People with Irritable Bowel Syndrome — Article Content Not](https://medichelpline.com/clinical-feed/frontiers-in-immunology-17-risk-of-systemic-rheumatic-diseases-in-people-with-irritable-bowel-syndrome-a.md)

## Navigation
- [← Back to Pulmonology Feed](https://medichelpline.com/clinical-feed/pulmonology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.